RESUMEN
In the present report, we describe the synthesis and structure-activity relationships of novel "four-arm" dihydropyrazoline compounds designed as peripherally restricted antagonists of cannabinoid-1 receptor (CB1R). A series of racemic 3,4-diarylpyrazolines were synthesized and evaluated initially in CB1 receptor binding assays. The novel compounds, designed to limit brain penetrance and decreased lipophilicity, showed high affinity for CB1R and potent in vitro CB1R antagonist activities. Promising compounds with potent CB1R activity were evaluated in tissue distribution studies. Compounds 6a, 6f, and 7c showed limited brain penetrance attesting to its peripheral restriction. The 4S-enantiomer of these compounds further showed a stereoselective affinity for the CB1 receptor and behaved as inverse agonists. In vivo studies on food intake and body weight reduction in diet-induced obese (DIO) mice showed that these compounds could serve as potential leads for the development of selective CB1R antagonists with improved potency and peripheral restriction.
Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Antagonistas de Receptores de Cannabinoides/uso terapéutico , Obesidad/tratamiento farmacológico , Pirazoles/uso terapéutico , Receptor Cannabinoide CB1/metabolismo , Animales , Fármacos Antiobesidad/síntesis química , Fármacos Antiobesidad/metabolismo , Peso Corporal/efectos de los fármacos , Encéfalo/metabolismo , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/metabolismo , Dieta Alta en Grasa , Agonismo Inverso de Drogas , Interacciones Hidrofóbicas e Hidrofílicas , Masculino , Ratones Endogámicos C57BL , Estructura Molecular , Pirazoles/síntesis química , Pirazoles/metabolismo , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Given that neuronal degeneration in Alzheimer's disease (AD) is caused by the combination of multiple neurotoxic insults, current directions in the research of novel therapies to treat this disease attempts to design multitarget strategies that could be more effective than the simply use of acetylcholinesterase inhibitors; currently, the most used therapy for AD. One option, explored recently, is the synthesis of new analogues of cannabinoids that could competitively inhibit the acetylcholinesterase (AChE) enzyme and showing the classic neuroprotective profile of cannabinoid compounds. In this work, molecular docking has been used to design some cannabinoid analogues with such multitarget properties, based on the similarities of donepezil and Δ9-tetrahydrocannabinol. The analogues synthesized, compounds 1 and 2, demonstrated to have two interesting characteristics in different in vitro assays: competitive inhibition of AChE and competitive antagonism at the CB1/CB2 receptors. They are highly lipophilic, highlighting that they could easily reach the CNS, and apparently presented a low toxicity. These results open the door to the synthesis of new compounds for a more effective treatment of AD.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Antagonistas de Receptores de Cannabinoides/farmacología , Cannabinoides/farmacología , Inhibidores de la Colinesterasa/farmacología , Simulación del Acoplamiento Molecular , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/enzimología , Enfermedad de Alzheimer/patología , Sitios de Unión , Encéfalo/enzimología , Encéfalo/patología , Antagonistas de Receptores de Cannabinoides/síntesis química , Cannabinoides/síntesis química , Línea Celular Tumoral , Inhibidores de la Colinesterasa/síntesis química , Diseño Asistido por Computadora , Diseño de Fármacos , Proteínas Ligadas a GPI/antagonistas & inhibidores , Proteínas Ligadas a GPI/metabolismo , Humanos , Neuronas/enzimología , Neuronas/patología , Fármacos Neuroprotectores/química , Unión Proteica , Conformación Proteica , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/antagonistas & inhibidores , Receptor Cannabinoide CB2/metabolismo , Relación Estructura-ActividadRESUMEN
Synthesis and pharmacological evaluation of a new series of cannabinoid receptor antagonists of indazole ether derivatives have been performed. Pharmacological evaluation includes radioligand binding assays with [3H]-CP55940 for CB1 and CB2 receptors and functional activity for cannabinoid receptors on isolated tissue. In addition, functional activity of the two synthetic cannabinoids antagonists 18 (PGN36) and 17 (PGN38) were carried out in the osteoblastic cell line MC3T3-E1 that is able to express CB2R upon osteogenic conditions. Both antagonists abolished the increase in collagen type I gene expression by the well-known inducer of bone activity, the HU308 agonist. The results of pharmacological tests have revealed that four of these derivatives behave as CB2R cannabinoid antagonists. In particular, the compounds 17 (PGN38) and 18 (PGN36) highlight as promising candidates as pharmacological tools.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/farmacología , Cannabinoides/farmacología , Éteres/farmacología , Indazoles/farmacología , Receptores de Cannabinoides/metabolismo , Células 3T3 , Animales , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/química , Cannabinoides/química , Relación Dosis-Respuesta a Droga , Éteres/síntesis química , Éteres/química , Indazoles/síntesis química , Indazoles/química , Ratones , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Drugs selectively targeting CB2 hold promise for treating neurodegenerative disorders, inflammation, and pain while avoiding psychotropic side effects mediated by CB1. The mechanisms underlying CB2 activation and signaling are poorly understood but critical for drug design. Here we report the cryo-EM structure of the human CB2-Gi signaling complex bound to the agonist WIN 55,212-2. The 3D structure reveals the binding mode of WIN 55,212-2 and structural determinants for distinguishing CB2 agonists from antagonists, which are supported by a pair of rationally designed agonist and antagonist. Further structural analyses with computational docking results uncover the differences between CB2 and CB1 in receptor activation, ligand recognition, and Gi coupling. These findings are expected to facilitate rational structure-based discovery of drugs targeting the cannabinoid system.
Asunto(s)
Subunidades alfa de la Proteína de Unión al GTP Gi-Go/química , Receptor Cannabinoide CB2/química , Transducción de Señal , Animales , Sitios de Unión , Células CHO , Agonistas de Receptores de Cannabinoides/síntesis química , Agonistas de Receptores de Cannabinoides/farmacología , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacología , Cricetinae , Cricetulus , Microscopía por Crioelectrón , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Humanos , Simulación del Acoplamiento Molecular , Unión Proteica , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/antagonistas & inhibidores , Receptor Cannabinoide CB2/metabolismo , Células Sf9 , SpodopteraRESUMEN
Peripherally restricted CB1 receptor antagonists may be useful in treating metabolic syndrome, diabetes, liver diseases, and gastrointestinal disorders. Clinical development of the centrally acting CB1 inverse agonist otenabant (1) was halted due to its potential of producing adverse effects. SAR studies of 1 are reported herein with the objective of producing peripherally restricted analogues. Crystal structures of hCB1 and docking studies with 1 indicate that the piperidine group could be functionalized at the 4-position to access a binding pocket that can accommodate both polar and nonpolar groups. The piperidine is studied as a linker, functionalized with alkyl, heteroalkyl, aryl, and heteroaryl groups using a urea connector. Orally bioavailable and peripherally selective compounds have been produced that are potent inverse agonists of hCB1 with exceptional selectivity for hCB1 over hCB2. Compound 38 blocked alcohol-induced liver steatosis in mice and has good ADME properties for further development.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/farmacología , Piperidinas/farmacología , Purinas/farmacología , Receptor Cannabinoide CB1/agonistas , Animales , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/metabolismo , Sistema Enzimático del Citocromo P-450/metabolismo , Perros , Agonismo Inverso de Drogas , Hígado Graso/patología , Hígado Graso/prevención & control , Femenino , Humanos , Hígado/patología , Células de Riñón Canino Madin Darby , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Estructura Molecular , Piperidinas/síntesis química , Piperidinas/metabolismo , Purinas/síntesis química , Purinas/metabolismo , Ratas Sprague-Dawley , Receptor Cannabinoide CB1/metabolismo , Relación Estructura-ActividadRESUMEN
The discovery of novel modulators of the cannabinoid system is a current topic in medicinal chemistry. In this paper, we report nine novel carboxamides designed as hybrids of Fubinaca family compounds and Rimonabant. These hybrids were obtained by linking the 1-benzyl-2,5-dichloroindazole-3-carboxylic acid to different amino acids bearing a hydrophobic side chain and three different C-terminus. The new chemical entities were tested in vitro to evaluate their bioactivity by means of receptor binding assays and [35S]GTPγS stimulation assays to reveal their affinity and potency. We found that all compounds were able to bind to the cannabinoid receptors in the low nanomolar range with a marked selectivity towards the CB1 cannabinoid receptor. Some of them are full agonists, whereas the others act as partial agonists. These molecules could be potentially used as anti-obesity agents, antiemetic and analgesics.
Asunto(s)
Antagonistas de Receptores de Cannabinoides , Piperidinas , Pirazoles , Animales , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/farmacología , Piperidinas/síntesis química , Piperidinas/química , Piperidinas/farmacología , Pirazoles/síntesis química , Pirazoles/química , Pirazoles/farmacología , Ratas , Ratas Wistar , RimonabantRESUMEN
In recent years, cannabinoid typeâ 2 receptors (CB2 R) have emerged as promising therapeutic targets in a wide variety of diseases. Selective ligands of CB2 R are devoid of the psychoactive effects typically observed for CB1 R ligands. Based on our recent studies on a class of pyridazinone 4-carboxamides, further structural modifications of the pyridazinone core were made to better investigate the structure-activity relationships for this promising scaffold with the aim to develop potent CB2 R ligands. In binding assays, two of the new synthesized compounds [6-(3,4-dichlorophenyl)-2-(4-fluorobenzyl)-cis-N-(4-methylcyclohexyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide (2) and 6-(4-chloro-3-methylphenyl)-cis-N-(4-methylcyclohexyl)-3-oxo-2-pentyl-2,3-dihydropyridazine-4-carboxamide (22)] showed high CB2 R affinity, with Ki values of 2.1 and 1.6â nm, respectively. In addition, functional assays of these compounds and other new active related derivatives revealed their pharmacological profiles as CB2 R inverse agonists. Compound 22 displayed the highest CB2 R selectivity and potency, presenting a favorable inâ silico pharmacokinetic profile. Furthermore, a molecular modeling study revealed how 22 produces inverse agonism through blocking the movement of the toggle-switch residue, W6.48.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/farmacología , Piridazinas/farmacología , Receptor Cannabinoide CB2/metabolismo , Animales , Benzoxazinas/antagonistas & inhibidores , Benzoxazinas/farmacología , Sitios de Unión , Células CHO , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacocinética , Antagonistas de Receptores de Cannabinoides/toxicidad , Cricetulus , AMP Cíclico/metabolismo , Agonismo Inverso de Drogas , Humanos , Ligandos , Simulación del Acoplamiento Molecular , Estructura Molecular , Morfolinas/antagonistas & inhibidores , Morfolinas/farmacología , Naftalenos/antagonistas & inhibidores , Naftalenos/farmacología , Piridazinas/síntesis química , Piridazinas/farmacocinética , Piridazinas/toxicidad , Receptor Cannabinoide CB2/química , Relación Estructura-ActividadRESUMEN
While equilibrium binding affinities and in vitro functional antagonism of CB1 receptor antagonists have been studied in detail, little is known on the kinetics of their receptor interaction. In this study, we therefore conducted kinetic assays for nine 1-(4,5-diarylthiophene-2-carbonyl)-4-phenylpiperidine-4-carboxamide derivatives and included the CB1 antagonist rimonabant as a comparison. For this we newly developed a dual-point competition association assay with [3H]CP55940 as the radioligand. This assay yielded Kinetic Rate Index (KRI) values from which structure-kinetics relationships (SKR) of hCB1 receptor antagonists could be established. The fast dissociating antagonist 6 had a similar receptor residence time (RT) as rimonabant, i.e. 19 and 14â¯min, respectively, while the slowest dissociating antagonist (9) had a very long RT of 2222â¯min, i.e. pseudo-irreversible dissociation kinetics. In functional assays, 9 displayed insurmountable antagonism, while the effects of the shortest RT antagonist 6 and rimonabant were surmountable. Taken together, this study shows that hCB1 receptor antagonists can have very divergent RTs, which are not correlated to their equilibrium affinities. Furthermore, their RTs appear to define their mode of functional antagonism, i.e. surmountable vs. insurmountable. Finally, based on the recently resolved hCB1 receptor crystal structure, we propose that the differences in RT can be explained by a different binding mode of antagonist 9 from short RT antagonists that is able to displace unfavorable water molecules. Taken together, these findings are of importance for future design and evaluation of potent and safe hCB1 receptor antagonists.
Asunto(s)
Antagonistas de Receptores de Cannabinoides , Receptor Cannabinoide CB1/metabolismo , Animales , Unión Competitiva , Células CHO , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/metabolismo , Cricetulus , Ciclohexanoles/metabolismo , Cinética , Ligandos , Unión Proteica , Ensayo de Unión Radioligante , Relación Estructura-ActividadRESUMEN
Selective CB2 agonists represent an attractive therapeutic strategy for the treatment of a variety of diseases without psychiatric side effects mediated by the CB1 receptor. We carried out a rational optimization of a black market designer drug SDB-001 that led to the identification of potent and selective CB2 agonists. A 7-methoxy or 7-methylthio substitution at the 3-amidoalkylindoles resulted in potent CB2 antagonists (27 or 28, IC50 = 16-28 nM). Replacement of the amidoalkyls from 3-position to the 2-position of the indole ring dramatically increased the agonist selectivity on the CB2 over CB1 receptor. Particularly, compound 57 displayed a potent agonist activity on the CB2 receptor (EC50 = 114-142 nM) without observable agonist or antagonist activity on the CB1 receptor. Furthermore, 57 significantly alleviated the clinical symptoms and protected the murine central nervous system from immune damage in an experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis.
Asunto(s)
Adamantano/análogos & derivados , Agonistas de Receptores de Cannabinoides/uso terapéutico , Indoles/uso terapéutico , Esclerosis Múltiple/tratamiento farmacológico , Receptor Cannabinoide CB2/agonistas , Adamantano/síntesis química , Adamantano/farmacocinética , Adamantano/uso terapéutico , Animales , Células CHO , Agonistas de Receptores de Cannabinoides/síntesis química , Agonistas de Receptores de Cannabinoides/farmacocinética , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacología , Cricetulus , Femenino , Indoles/síntesis química , Indoles/farmacocinética , Ligandos , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB2/antagonistas & inhibidores , Relación Estructura-ActividadRESUMEN
Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This has led to the search for more peripherally restricted CB1R antagonists, one of which is ibipinabant. However, this 3,4-diarylpyrazoline derivative showed muscle toxicity in a pre-clinical dog study with mitochondrial dysfunction. Here, we studied the molecular mechanism by which ibipinabant induces mitochondrial toxicity. We observed a strong cytotoxic potency of ibipinabant in C2C12 myoblasts. Functional characterization of mitochondria revealed increased cellular reactive oxygen species generation and a decreased ATP production capacity, without effects on the catalytic activities of mitochondrial enzyme complexes I-V or the complex specific-driven oxygen consumption. Using in silico off-target prediction modelling, combined with in vitro validation in isolated mitochondria and mitoplasts, we identified adenine nucleotide translocase (ANT)-dependent mitochondrial ADP/ATP exchange as a novel molecular mechanism underlying ibipinabant-induced toxicity. Minor structural modification of ibipinabant could abolish ANT inhibition leading to a decreased cytotoxic potency, as observed with the ibipinabant derivative CB23. Our results will be instrumental in the development of new types of safer CB1R antagonists.
Asunto(s)
Adenosina Trifosfato/antagonistas & inhibidores , Amidinas/química , Fármacos Antiobesidad/química , Antagonistas de Receptores de Cannabinoides/química , Mitocondrias/efectos de los fármacos , Translocasas Mitocondriales de ADP y ATP/antagonistas & inhibidores , Pirazoles/química , Adenosina Difosfato/metabolismo , Adenosina Trifosfato/metabolismo , Amidinas/síntesis química , Amidinas/toxicidad , Animales , Fármacos Antiobesidad/síntesis química , Fármacos Antiobesidad/toxicidad , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/toxicidad , Línea Celular , Perros , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Proteínas del Complejo de Cadena de Transporte de Electrón/antagonistas & inhibidores , Proteínas del Complejo de Cadena de Transporte de Electrón/metabolismo , Humanos , Ratones , Mitocondrias/metabolismo , Translocasas Mitocondriales de ADP y ATP/metabolismo , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Mioblastos/citología , Mioblastos/efectos de los fármacos , Mioblastos/enzimología , Obesidad/tratamiento farmacológico , Obesidad/patología , Consumo de Oxígeno/efectos de los fármacos , Pirazoles/síntesis química , Pirazoles/farmacología , Pirazoles/toxicidad , Especies Reactivas de Oxígeno/agonistas , Especies Reactivas de Oxígeno/metabolismo , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB1/metabolismo , Relación Estructura-ActividadRESUMEN
6-Alkoxy-5-aryl-3-pyridincarboxamides, including the brain-penetrant compound 14G: [5-(4-chlorophenyl)-6-(cyclopropylmethoxy)-N-[(1R,2R)-2-hydroxy-cyclohexyl]-3-pyridinecarboxamide] and its peripherally restricted analog 14H: [5-(4-chlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-methoxyethoxy)-3-pyridinecarboxamide], have been recently introduced as selective, high-affinity antagonists of the human cannabinoid-1 receptor (hCB1R). Binding analyses revealed two orders of magnitude lower affinity of these compounds for mouse and rat versus human CB1R, whereas the affinity of rimonabant is comparable for all three CB1Rs. Modeling of ligand binding to CB1R and binding assays with native and mutant (Ile105Met) hCB1Rs indicate that the Ile105 to Met mutation in rodent CB1Rs accounts for the species-dependent affinity of 14G: and 14H: . Our work identifies Ile105 as a new pharmacophore component for developing better hCB1R antagonists and invalidates rodent models for assessing the antiobesity efficacy of 14G: and 14H: .
Asunto(s)
Encéfalo/metabolismo , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacología , Niacinamida/análogos & derivados , Piperidinas/farmacología , Pirazoles/farmacología , Receptor Cannabinoide CB1/genética , Animales , Antagonistas de Receptores de Cannabinoides/química , Células HEK293 , Humanos , Isoleucina/metabolismo , Ratones , Modelos Moleculares , Niacinamida/síntesis química , Niacinamida/química , Niacinamida/farmacología , Piperidinas/química , Pirazoles/química , Ratas , Receptor Cannabinoide CB1/metabolismo , Rimonabant , Especificidad de la Especie , Relación Estructura-Actividad , Difracción de Rayos XRESUMEN
Since the identification of the endocannabinoid system, two Gâ protein-coupled receptors (GPCRs) of this complex system were identified and characterized: cannabinoid receptors typeâ 1 (CB1R) and typeâ 2 (CB2R). In addition to orthosteric and subsequently allosteric ligands, new strategies have been used to target CBRs. Bivalent ligands and multifunctional ligands acting at diverse biological targets have been designed, synthesized, and characterized for both CBRs. Due to their altered receptor binding and pharmacological profiles, they are interesting tools to explore CBR functions and their interactions with other physiological systems. Moreover, this approach may bear therapeutic advantages in the therapy of CBR-related disorders, especially multifactorial diseases. Promising prospects include anorectics with fewer side effects, analgesics with decreased tolerance, and therapeutics with multiple pharmacological activities for the treatment of cancer, inflammation, multiple sclerosis, Huntington's and Alzheimer's diseases.
Asunto(s)
Agonistas de Receptores de Cannabinoides/química , Agonistas de Receptores de Cannabinoides/farmacología , Antagonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/farmacología , Diseño de Fármacos , Receptores de Cannabinoides/metabolismo , Agonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/síntesis química , Humanos , Ligandos , Estructura MolecularRESUMEN
Cannabinoid receptors, belonging to the superfamily of G-protein coupled receptors, play a major role in pathophysiology of a wide range of disparate diseases. Cannabinoid CB2 receptor, which mainly locates in peripheral tissues, represents as a promising drug target for the treatment of pain, osteoporosis, liver disorders, and so on without serious CNS side effects. In the past decades, the identification and optimization of selective ligands for the CB2 receptor has been a major objective in drug discovery. In the present review, we describe recent advances in the development of novel chemotypes of the CB2 receptor selective ligands, and give a simple discussion for the corresponding structure-activity relationships of them.
Asunto(s)
Agonistas de Receptores de Cannabinoides/síntesis química , Agonistas de Receptores de Cannabinoides/farmacología , Antagonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/farmacología , Descubrimiento de Drogas , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/antagonistas & inhibidores , Animales , Agonistas de Receptores de Cannabinoides/análisis , Agonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/análisis , Antagonistas de Receptores de Cannabinoides/química , Humanos , Ligandos , Receptor Cannabinoide CB2/metabolismo , Relación Estructura-ActividadRESUMEN
Attenuation of increased endocannabinoid signaling with a CB1R neutral antagonist might offer a new therapeutic direction for treatment of alcohol abuse. We have recently reported that a monohydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies. In the current study, we show that systematic modification of an aminoalkylindole scaffold identified two new compounds with dual CB1R antagonist/CB2R agonist activity. Similar to the CB1R antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration without affecting total fluid intake and block the development of alcohol-conditioned place preference. Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.
Asunto(s)
Alcoholismo/tratamiento farmacológico , Agonistas de Receptores de Cannabinoides/síntesis química , Antagonistas de Receptores de Cannabinoides/síntesis química , Indoles/síntesis química , Receptores de Cannabinoides/metabolismo , Animales , Células CHO , Agonistas de Receptores de Cannabinoides/química , Agonistas de Receptores de Cannabinoides/farmacología , Antagonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/farmacología , Condicionamiento Clásico/efectos de los fármacos , Cricetinae , Cricetulus , Diseño de Fármacos , Agonismo Inverso de Drogas , Etanol/administración & dosificación , Etanol/farmacología , Humanos , Indoles/química , Indoles/farmacología , Ligandos , Ratones , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB2/agonistas , Autoadministración , Relación Estructura-ActividadRESUMEN
A series of bivalent cannabinoid ligands is proposed. The synthesis of double amides based on the rimonabant structure separated by an alkyl chain and the evaluation of their affinities for cannabinoid receptors are reported. The data of 4d confirmed that a bivalent structure is a suitable scaffold for CB1 cannabinoid receptor binding. The compound 4d was selected for in vitro and in vivo pharmacological evaluations. Moreover, intraperitoneal administration of 4d to food-deprived rats resulted in a dose-dependent inhibition of feeding that was maintained up to 240 min.
Asunto(s)
Antagonistas de Receptores de Cannabinoides/síntesis química , Diseño de Fármacos , Conducta Alimentaria/efectos de los fármacos , Piperidinas/síntesis química , Pirazoles/síntesis química , Receptor Cannabinoide CB1/metabolismo , Animales , Antagonistas de Receptores de Cannabinoides/química , Antagonistas de Receptores de Cannabinoides/farmacología , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Privación de Alimentos , Humanos , Ligandos , Masculino , Ratones , Ratones Endogámicos ICR , Estructura Molecular , Piperidinas/química , Piperidinas/farmacología , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Corteza Prefrontal/patología , Unión Proteica , Pirazoles/química , Pirazoles/farmacología , Ensayo de Unión Radioligante , Receptor Cannabinoide CB1/genética , Rimonabant , Relación Estructura-Actividad , TransfecciónRESUMEN
Cannabinoid receptor 1 (CB1) antagonists are potentially useful for the treatment of several diseases. However, clinical development of several CB1 antagonists was halted due to central nervous system (CNS)-related side effects including depression and suicidal ideation in some users. Recently, studies have indicated that selective regulation of CB1 receptors in the periphery is a viable strategy for treating several important disorders. Past efforts to develop peripherally selective antagonists of CB1 have largely targeted rimonabant, an inverse agonist of CB1. Reported here are our efforts toward developing a peripherally selective CB1 antagonist based on the otenabant scaffold. Even though otenabant penetrates the CNS, it is unique among CB1 antagonists that have been clinically tested because it has properties that are normally associated with peripherally selective compounds. Our efforts have resulted in an orally absorbed compound that is a potent and selective CB1 antagonist with limited penetration into the CNS.
Asunto(s)
Compuestos de Bifenilo/química , Encéfalo/efectos de los fármacos , Antagonistas de Receptores de Cannabinoides/farmacología , Diseño de Fármacos , Purinas/química , Receptor Cannabinoide CB1/antagonistas & inhibidores , Sulfonamidas/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Calcio/metabolismo , Antagonistas de Receptores de Cannabinoides/síntesis química , Permeabilidad de la Membrana Celular/efectos de los fármacos , Células Cultivadas , Perros , Masculino , Modelos Moleculares , Estructura Molecular , Purinas/síntesis química , Purinas/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptor Cannabinoide CB1/metabolismo , Relación Estructura-Actividad , Sulfonamidas/síntesis químicaRESUMEN
The synthesis of three series of novel 4-alkyl-5-(5'-chlorothiophen-2'-yl)-pyrazole-3-carbamoyl analogues of rimonabant with affinity for the CB1 cannabinoid receptor subtype is reported. Amongst the novel derivatives, compounds 21j, 22a, 22c, and 22f showed affinity values expressed as Ki ranging from 5.5 to 9.0 nM. Derivative 23e revealed a good CB1 affinity (K(i) = 11.7 nM) and the highest CB1 selectivity of the whole series (K(i)CB2/K(i)CB1 = 384.6). These new compounds appeared to be able to pass the blood brain barrier and to counteract the activity of cannabinoid agonist. According to the results of mice vas deferens assays, as in the case of rimonabant, derivatives 21a, 22a, and 22b showed inverse agonist activity. In contrast, as a preliminary result to be confirmed, compound 23a exhibited neutral antagonist profile. According to the data obtained through an acute animal model, selected compounds 21a, 22a, and 23a evidenced the capability to significantly reduce food intake. At specific conditions, the effect of the novel compounds were higher than that induced by rimonabant. Amongst the novel CB1 antagonist compounds, 23a may represent a useful candidate agent for the treatment of obesity and its metabolic complications, with reduced side effects relative to those instead observed with rimonabant.